Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study.
Lung
; 202(1): 41-51, 2024 02.
Article
in En
| MEDLINE
| ID: mdl-38252134
ABSTRACT
BACKGROUND:
The determinants linked to the short- and long-term improvement in lung function in patients with severe eosinophilic asthma (SEA) on biological treatment (BioT) remain elusive.OBJECTIVE:
We sought to identify the predictors of early and late lung function improvement in patients with SEA after BioT.METHODS:
140 adult patients with SEA who received mepolizumab, dupilumab, or reslizumab were followed up for 6 months to evaluate improvement in forced expiratory volume in one second (FEV1). Logistic regression was used to determine the association between potential prognostic factors and improved lung function at 1 and 6 months of treatment.RESULTS:
More than a third of patients with SEA using BioT showed early and sustained improvements in FEV1 after 1 month. A significant association was found between low baseline FEV1 and high blood eosinophil count and sustained FEV1 improvement after 1 month (0.54 [0.37-0.79] and 1.88 [1.28-2.97] odds ratios and 95% confidence interval, respectively). Meanwhile, among patients who did not experience FEV1 improvement after 1 month, 39% exhibited improvement at 6 months follow-up. A high ACT score measured at this visit was the most reliable predictor of late response after 6 months of treatment (OR and 95% CI 1.75 [1.09-2.98]).CONCLUSION:
Factors predicting the efficacy of biological agents that improve lung function in SEA vary according to the stage of response.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Pulmonary Eosinophilia
/
Asthma
/
Biological Products
/
Anti-Asthmatic Agents
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Lung
Year:
2024
Type:
Article
Affiliation country:
South Korea